Ongoing projects have increased the stem cell ratio in Limbustem’s therapy from 50% to 70%, enhancing clinical success and ensuring a biomimetic microenvironment through innovations like amniotic membrane extract (AME).
Welcome to LimbuStem
Cure for Cornea
Limbustem develops innovative cell therapies for ocular diseases, offering patients safe and effective vision restoration. For investors, it promises scalable solutions in a high-demand market, driven by cutting-edge R&D and proven clinical success.
A company that goes from award to award
Limbustem has earned prestigious national and international awards, showcasing its groundbreaking innovation in ocular therapies. From TÜBİTAK grants to recognition in leading medical competitions, our achievements highlight excellence in research, product development, and clinical impact.
About Us
Limbstem is a research and development (R&D) company in the field of Ophthalmology that produces and distributes advanced medical therapeutic products, specifically for corneal and ocular surface problems. The company is an academic spinoff focusing on life sciences and biotechnology. Its headquarters is in Ege Technopark Izmir, Turkey. Limbustem works in deep technology in the field of health and progresses in the production of cellular/biological products, has also gained specialised experience in completing the requirements of legal regulations based on EMA on relevant issues.
Latest News
Women TechEU – Winner of the 2nd Call
Limbustem is a spin-off company specialising in the development of advanced medical therapeutics for ophthalmology. Our core activity is a treatment for limbal stem cell deficiency leading to blindness. We started developing the core product 15yrs ago in academia and launched it as MVP in the local market in 2023. We have continued R&D and developed a new technique that improves the product. We aim to offer it as the most effective treatment in the global market with unrivalled clinical success.
Successful Clinical Trials for Limbustem PRO AMEX
Limbustem has announced positive clinical outcomes in its trials, an innovative therapy for limbal stem cell deficiency (LSCD). In a recent study, 80% of patients exhibited improvement in clinical findings after one year of treatment, underscoring the product’s potential to restore vision and enhance quality of life.
Expansion into the European Market
We are delighted to announce partnerships with a number of highly regarded local hospitals and research centres. These collaborations will enhance our clinical research capabilities and provide training for ophthalmologists in the use of our innovative therapies.
Partnerships with Leading Healthcare Institutions
Limbustem is pleased to announce that we will be actively developing Limbustem PRO AMEX over the next two years if the EIC grant application, which has passed the first stage this year, is favourably completed. Our team is working diligently to finalise international patent applications and compile preliminary clinical data in order to strengthen our position in the market.
Ongoing Research and Development
With the support of the EIC grant, Limbustem is actively developing Limbustem PRO AMEX over the next two years. Our team is working diligently to complete international patent applications and gather early clinical results to strengthen our position in the market.
